Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: December 8, 2021

DrugPatentWatch Database Preview

Patent: 9,161,988

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,161,988
Title:Multimeric peptide conjugates and uses thereof
Abstract: The present invention relates to multimeric (e.g., dimeric, trimeric) forms of peptide vectors that are capable of crossing the blood-brain barrier (BBB) or efficiently entering particular cell types. These multimeric peptide vectors, when conjugated to agents (e.g., therapeutic agents) are capable of transporting the agents across the BBB or into particular cell types. These compounds are therefore particularly useful in the treatment of neurological diseases.
Inventor(s): Castaigne; Jean-Paul (Mont-Royal, CA), Demeule; Michel (Beaconsfield, CA), Che; Christian (Longueuil, CA), Thiot; Carine (Montreal, CA), Gagnon; Catherine (Montreal-Nord, CA), Lawrence; Betty (Bolton, CA)
Assignee: Angiochem Inc. (Montreal, CA)
Application Number:13/382,069
Patent Claims:see list of patent claims

Details for Patent 9,161,988

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 1978-01-10 ⤷  Free Forever Trial 2029-07-02
Organon Teknika Corporation Llc TICE BCG bcg live For Injection 102821 1989-06-21 ⤷  Free Forever Trial 2029-07-02
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Free Forever Trial 2029-07-02
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Free Forever Trial 2029-07-02
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 1989-06-01 ⤷  Free Forever Trial 2029-07-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.